Work

A randomized, active-controlled clinical trial of fluocinolone acetonide 0.19 mg intravitreal implant for diabetic macular edema: Reductions in injection treatment burden – results from the NEW DAY study

Year: 2026

Type: conference-paper

Abstract: Purpose: NEW DAY was a prospective, randomized, active-controlled, multicenter, phase 4, 18-month study (ClinicalTrials.gov ID NCT04469595). The study assessed the efficacy and safety of the fluocinolone acetonide (FAc; 0.19 mg) intravitreal implant as a baseline therapy in patients with center-involving [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/26doc133

Authors: Riemann, Christopher D., Singer, Michael, Wykoff, Charles C., Gonzalez, Victor H., Weng, Christina Y., Alkhatib, Kamel, Pao, Mary

Institutions: Cincinnati Eye Institute, Medical Center Ophthalmology Associates, Retina Consultants of Texas, Valley Retina Institute, Baylor College of Medicine, ANI Pharmaceuticals (United States)

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7165040599

FWCI:

Cites:

Cited by:

Related to: